Loading clinical trials...

Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia | Clinical Trials | Clareo Health

COMPLETEDNA

Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia

Effects of a Twenty-Four-Week Pomegranate Seed Oil Supplementation in Palliative Care Patients With Advanced Dementia: A Double Blind, Randomized Controlled Clinical Study

NCT07432763•Panhellenic Federation of Alzheimer's Disease and Related Disorders

View on ClinicalTrials.gov

Summary

The goal of this clinical study is to learn if Pomegranate Seed Oil supplementation works to combat urinary tract infections, recurrenturinary tract infections, or pneumonia and contributes to the tapering or discontinuation of antipsychotics in palliative care patients withadvanced dementia. The main questions it aims to answer are: * Does Pomegranate Seed Oil supplementation reduce the likelihood of developing a urinary tract infection? * Does Pomegranate Seed Oil supplementation prevent UTI reinfection? * Does Pomegranate Seed Oil supplementation reduce the likelihood of pneumonia? * Does Pomegranate Seed Oil supplementation contribute to the tapering or discontinuation of antipsychotics? Researchers will compare Pomegranate Seed Oil to care-as-usual to see if Pomegranate Seed Oil supplementation can increase quality of care in palliative care patients with advanced dementia.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged 65+
•Dementia diagnosis (major neurocognitive disorder) according to the criteria Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) or the International Statistical Classification of Diseases and Related Health Problems (ICD-11)
•Participants classified as Stage 7, Profound Cognitive Decline on the Global Deterioration Scale, corresponding to advanced dementia
•AD related biomarkers in CSF
•Caregiver consent for study participation

Exclusion Criteria

•History of allergy to the supplement or any of its components
•Prior diagnosis of Schizophrenia Spectrum and Other Psychotic Disorders according to the criteria Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) or the International Statistical Classification of Diseases and Related Health Problems (ICD-11)
•Participants having medical history of recurring urinary tract infections
•Participants having medical history of renal or liver failure
•Participants concurrently participating in other clinical studies

Locations (1)

Palliative Care Centre "Panagia Glykofilousa"

Thessaloniki, Central Macedonia, Greece

Key Dates

Start Date

May 1, 2024

Primary Completion Date

October 31, 2024

Completion Date

October 31, 2024

Last Updated

February 25, 2026

Enrollment

ACTUAL participants

Conditions

Urinary Tract Infections (UTIs)Urinary Tract Infection, RecurrentAntipsychotics DiscontinuationAntipsychotics Tapering

Interventions

Pomegranate Seed Oil Supplementation in Palliative Care Patients with Advanced Dementia

DIETARY_SUPPLEMENT

Care-as-usual

OTHER

Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections

NCT07233473

Urinary Tract Infections (UTIs)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions